Payment overview · 2025
General Payments
$115,149.54
170 reported records · 31 companies
Healthcare provider profile · identity verified
Craig Michael Walker, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · HOUMA, LA · NPI 1548267529
Verified facts
What the public records show
CMS Open Payments records show Craig Michael Walker, MD received $115,149.54 in general payments during 2025 across 170 reported records.
Novo Nordisk Inc accounted for 49.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57,327.44 | 49.8% | 45 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $32,981.55 | 28.6% | 28 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $8,680.49 | 7.5% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $4,100.00 | 3.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $2,920.72 | 2.5% | 8 | 2025 |
| ASAHI INTECC CO., LTD. | Unresolved — no canonical attribution shown | $2,264.75 | 2.0% | 3 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $2,251.94 | 2.0% | 7 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $793.22 | 0.7% | 9 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $579.63 | 0.5% | 2 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $554.65 | 0.5% | 7 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $354.63 | 0.3% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $302.53 | 0.3% | 3 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $289.10 | 0.2% | 3 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $282.50 | 0.2% | 11 | 2025 |
| Nipro Medical Corporation | Unresolved — no canonical attribution shown | $239.09 | 0.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$169.97 | 0.1% | 6 | 2025 |
| Avantec Vascular Corporation | Unresolved — no canonical attribution shown | $142.63 | 0.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $125.74 | 0.1% | 1 | 2025 |
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $111.15 | 0.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $105.20 | 0.1% | 2 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $103.92 | 0.1% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $97.91 | 0.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $97.68 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.98 | 0.1% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $50.48 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.58 | 0.0% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $33.53 | 0.0% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $32.61 | 0.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.58 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.38 | 0.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $16.96 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,420.25 | 16 |
| Consulting Fee | $27,525.00 | 10 |
| Honoraria | $9,800.00 | 2 |
| Long term medical supply or device loan | $7,900.00 | 3 |
| Food and Beverage | $7,593.61 | 126 |
| Travel and Lodging | $3,779.64 | 11 |
| Gift | $98.77 | 1 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57,124.67 | 37 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $24,301.22 | 12 | 2025 |
Source payment records
|
|||||
| US EQ Undivided Normalized: us eq undivided |
Device | Philips North America LLC | $7,800.00 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $6,032.51 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $4,100.00 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $2,920.72 | 8 | 2025 |
Source payment records
|
|||||
| VenaCure 1470 Pro Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $2,400.00 | 2 | 2025 |
Source payment records
|
|||||
| Asahi Interventional Radiology Wires Normalized: asahi interventional radiology wires |
Device | ASAHI INTECC USA, INC. | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $587.23 | 9 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $450.00 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC., Haemonetics Corporation | $393.65 | 12 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $302.53 | 3 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $301.80 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $289.10 | 3 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $251.94 | 6 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $242.41 | 5 | 2025 |
Source payment records
|
|||||
| Hemodialysis System Normalized: hemodialysis system |
Device | Nipro Medical Corporation | $239.09 | 3 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTA Normalized: selution slr pta |
Device | CORDIS US CORP. | $228.64 | 2 | 2025 |
Source payment records
|
|||||
| Artemis Normalized: artemis |
Device | Penumbra, Inc. | $225.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $202.77 | 8 | 2025 |
Source payment records
|
|||||
| RADIAL 360 Normalized: radial 360 |
Device | CORDIS US CORP. | $196.40 | 3 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $148.80 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $129.63 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $129.63 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $125.74 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $105.20 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $105.20 | 2 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $103.92 | 1 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $99.18 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $97.91 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $97.91 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $97.68 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $90.28 | 3 | 2025 |
Source payment records
|
|||||
| BRITE TIP RADIANZ Normalized: brite tip radianz |
Device | CORDIS US CORP. | $66.38 | 1 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $50.69 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $50.48 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $40.12 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $39.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $33.58 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 148 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 37 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 896 | 233 |
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 488 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 484 | 134 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 363 | 106 |
| Alprazolam | Alprazolam | 355 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 351 | 117 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 288 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 80 |
| Furosemide | Furosemide | 232 | 68 |
| Diazepam | Diazepam | 228 | 44 |
| Losartan Potassium | Losartan Potassium | 213 | 68 |
| Cilostazol | Cilostazol | 204 | 66 |
| Jardiance | Empagliflozin | 191 | 43 |
| Carvedilol | Carvedilol | 190 | 61 |
| Repatha Sureclick | Evolocumab | 176 | 27 |
| Xarelto | Rivaroxaban | 175 | 43 |
| Telmisartan | Telmisartan | 172 | 50 |
| Eliquis | Apixaban | 148 | 37 |
| Lisinopril | Lisinopril | 144 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 44 |
| Spironolactone | Spironolactone | 133 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 34 |
| Sotalol | Sotalol Hcl | 113 | 27 |
| Potassium Chloride | Potassium Chloride | 109 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 21 |
| Nitroglycerin | Nitroglycerin | 84 | 33 |
| Ranolazine Er | Ranolazine | 78 | 13 |
| Ezetimibe | Ezetimibe | 76 | 29 |
| Prasugrel Hcl | Prasugrel Hcl | 71 | 28 |
| Gabapentin | Gabapentin | 70 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 70 | 19 |
| Atenolol | Atenolol | 58 | 17 |
| Lovastatin | Lovastatin | 55 | 15 |
| Mounjaro | Tirzepatide | 54 | 12 |
| Praluent Pen | Alirocumab | 49 | suppressed |
| Metformin Hcl | Metformin Hcl | 45 | 13 |
| Acebutolol Hcl | Acebutolol Hcl | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Metolazone | Metolazone | 41 | 15 |
| Warfarin Sodium | Warfarin Sodium | 41 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 15 |
| Irbesartan | Irbesartan | 39 | 12 |
| Allopurinol | Allopurinol | 37 | 11 |
| Omeprazole | Omeprazole | 33 | suppressed |
| Ozempic | Semaglutide | 29 | 13 |
| Valsartan | Valsartan | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Repatha Pushtronex | Evolocumab | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Colchicine | Colchicine | 14 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115,149.54 · 170 records | Novo Nordisk Inc | ABRE, ALPHAVAC, ANGIOVAC, AURYON LASER SYSTEM 100-120 VAC, Artemis, Asahi Interventional Radiology Wires, Asahi Peripheral Vascular Wires, Assure WCD, BRITE TIP RADIANZ, CAMZYOS, CARDIVA VASCADE 6/7F VCS, ELIQUIS, ENDOCROSS Device, ESPRIT, Flexitouch Plus, GORE VIABAHN Endoprosthesis with Heparin, General - Vascular Intervention, Hemodialysis System, IGT Devices Undivided, IN.PACT ADMIRAL, IV Other, Indigo System, Kerendia, LEQVIO, Labosys, LifeVest, METACROSS OTW, MYNX CONTROL VENOUS, NAVICROSS, NURTEC ODT, Nimbl, ONPATTRO, Ozempic, Paradise Ultrasound Renal Denervation System, Peripheral Vascular Undivided, RADIAL 360, REPATHA, SELUTION SLR PTA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, US EQ Undivided, VYNDAQEL, VenaCure 1470 Pro, WatchPATONE, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error